Biotech · Public company · Menlo Park, CA, US

Oruka Therapeutics, Inc.

Ticker ORKA · SEC CIK 0000907654

Track this companyFree. Adds Oruka Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials55 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

ORKA-001Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
ORKA-001 Induction DosePhase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
ORKA-001 Maintenance DosePhase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
ORKA-002Phase 2 · Hidradenitis Suppurativa (HS)ClinicalTrials.gov · fetched Nov 12, 2026
ORKA-002Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaPHASE2 · RECRUITING · started Aug 21, 2026ClinicalTrials.gov NCT07783542 · fetched Nov 12, 2026
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 19, 2026ClinicalTrials.gov NCT07474792 · fetched Nov 12, 2026
An Open-Label Extension Study of ORKA-001 in Participants With Plaque PsoriasisPHASE2 · RECRUITING · started Feb 23, 2026ClinicalTrials.gov NCT07449702 · fetched Nov 12, 2026
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 3, 2025ClinicalTrials.gov NCT07290569 · fetched Nov 12, 2026
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque PsoriasisPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 18, 2025ClinicalTrials.gov NCT07090330 · fetched Nov 12, 2026